In a regulatory filing, Vanda Pharmaceuticals (VNDA -1.2%) discloses that it seeks an award of $539M in its arbitration proceeding with Novartis (NVS -1.1%) over the licensing of Fanapt. Novartis, unsurprisingly, has filed a counter-claim. It expects the process to be completed in 12 to 18 months.
In a regulatory filing, Vanda Pharmaceuticals (VNDA) discloses that it has filed a patent infringement suit against Roxanne Laboratories' ANDA for generic versions of iloperidone oral tablets in seven dosages. Vanda claims Roxanne's filing infringes on patent no. 8,586,610 which does not expire until 2027.
Vanda Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders such as HETLIOZ, Fanapt and VLY-686.